> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Rozlytrek
- URL: https://www.fdaweb.com/regulatory-review-period-for-rozlytrek/
- Published: 2022-08-02T12:00:00.000Z
- Updated: 2026-09-14T17:54:25.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152422

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Genentech’s Rozlytrek tablets (entrectinib), indicated for treating certain adult patients with metastatic non-small cell lung cancer, among other indications. The review period is 1,968 days, of which 1,727 days occurred during the testing phase and 241 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-08-02/pdf/2022-16504.pdf?ref=fdaweb.com).